{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1164.29","meta":{"versionId":"4","lastUpdated":"2017-06-21T01:00:04.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"LUGPA Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2017-06-21"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.29","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113762.1.4.1164.29"}],"version":"20170621","name":"DenosumabForOsteoporosisTreatmentWithNonMetastaticProstateCancer","title":"Denosumab for osteoporosis treatment with non metastatic prostate cancer","status":"active","experimental":false,"date":"2017-06-21T01:00:04-04:00","publisher":"LUGPA Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: This set of values contains denosumab that is prescribed for osteoporosis in men with prostate cancer that is non metastatic to bone.),(Data Element Scope: The intent of this date element is to identify denosumab for treatment of osteoporosis in men with prostate cancer that is not metastatic to the bone.),(Inclusion Criteria: Injectible denosumab - 60 mg),(Exclusion Criteria: Injectible denosumab - 120 mg)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","concept":[{"code":"993452","display":"1 ML denosumab 60 MG/ML Prefilled Syringe"}]}]},"expansion":{"identifier":"urn:uuid:88df97d7-d4c4-4f0a-ba18-e73967d8a628","timestamp":"2023-12-10T22:31:07-05:00","total":1,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"993452","display":"1 ML denosumab 60 MG/ML Prefilled Syringe"}]}}